Pisu

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pisu

What is Pisu? A Dual-Action Upper Respiratory Combination

Property Description
Active Ingredients Pseudoephedrine HCl and Triprolidine HCl
Form Oral tablet or Oral liquid (syrup/suspension)
Pharmacological Class Upper Respiratory Combination
Common Use Temporary symptomatic relief of cold and allergy symptoms
Origin Synthetic

Pisu is a synthetic combination medication designated as an upper respiratory combination product. This classification reflects its design to simultaneously address multiple, related symptoms of the nasal passages and airways with a single formulation. The medicine is typically administered via the oral route and is available in common oral dosage forms, including tablets and liquids. Pisu is chemically defined by its core active substances, Pseudoephedrine HCl and Triprolidine HCl. The combination of these two distinct agents is clinically recognized for providing more comprehensive symptom relief than either agent used alone.

The Purpose of Pisu: Addressing Congestion and Allergy Symptoms

The general purpose of Pisu is to provide temporary symptomatic relief when a patient is experiencing both nasal congestion and hypersensitivity reactions—a typical scenario during severe cold periods or peak allergy seasons. This dual therapeutic benefit stems from the precise actions of its components, a mechanism widely supported by pharmacological studies. Pseudoephedrine functions as a potent nasal decongestant by initiating vasoconstriction to reduce mucosal swelling, which is the physical basis of nasal and sinus congestion. Conversely, Triprolidine is classified as a first-generation H1-receptor antagonist, blocking the effects of histamine to mitigate allergy-related symptoms such as sneezing and a runny nose. The use of this specific combination is further distinguished by its formulation which targets both nasal blockage and secretion issues simultaneously.

Regulatory References

  1. NIH/DailyMed

What side effects are possible with Pisu?

Possible Side Effects and Safety Information

The safety profile of the Pseudoephedrine and Triprolidine combination is documented in official regulatory sources, focusing on adverse reactions categorized by frequency and the organ system affected. The common adverse effects are primarily associated with the antihistamine component, while sympathomimetic effects stem from the decongestant.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the reported frequency in clinical use, which may vary by region or regulatory standard:

  • Common: Adverse events frequently reported include sedation (somnolence), disturbed attention, dizziness, headache, and dry mouth.
  • Uncommon: Less frequent effects include anxiety, nervousness, restlessness, insomnia, palpitations, tachycardia, tremor, blurred vision, and difficulty passing urine (dysuria).

System-Organ Classes and Serious Safety Concerns

Side effects are officially grouped by the physiological system involved. Significant involvement is noted in Nervous System Disorders (e.g., sedation) and Cardiac Disorders (e.g., tachycardia, palpitations).

The regulatory label documents serious adverse reactions that, though rare, are clinically significant. These include severe Hypersensitivity Reactions (e.g., angioedema, severe skin reactions) and severe Central Nervous System (CNS) effects such as convulsions, hallucinations, or psychosis.

Population-Specific Safety Notes

The official safety information includes specific considerations for certain patient groups:

  • Older Adults: This population may exhibit increased susceptibility to CNS effects (e.g., confusion) and a heightened risk of difficulty passing urine.
  • Pediatrics: Higher risk of paradoxical reactions, which may manifest as excitation or restlessness.

Effects such as sedation are generally more pronounced and common during the initial days of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose of Pisu, a combination of Pseudoephedrine and Triprolidine, results in a dual toxicity profile documented by government regulatory authorities.

Overdosage may manifest through significant Central Nervous System (CNS) effects, including restlessness, excitement, hallucinations, psychosis, and potentially progressing to convulsions or coma. Cardiovascular toxicity is also a documented clinical finding, presenting as hypertension and various arrhythmias, including tachycardia. Signs related to the antihistamine component, such as ataxia, tremor, and anticholinergic effects (e.g., dry mucous membranes), are also officially described.

Severe Outcomes Emergency Action Supportive Management
Hypertensive crisis, coma, death in pediatrics. Seek immediate medical attention or call the Poison Help line. Treatment is symptomatic and supportive; no specific antidote is known.

Urgent medical attention is required immediately if the affected individual has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened, as these are signs of potentially life-threatening overdose. The official prescribing information notes that the ingredients may produce convulsions and death in pediatric patients in overdosage, highlighting a specific risk in this population. Symptomatic treatment described includes the use of parenteral diazepam for CNS stimulation and beta-blockers for cardiovascular complications.

Therapeutic Uses of Pisu

What Pisu Treats: Main Uses and Benefits

Pisu (Pseudoephedrine and Triprolidine combination) is applied across domains where additional symptomatic support is needed involving symptoms related to physical discomfort in the upper respiratory system. It is specifically applicable in conditions characterized by periods of heightened symptoms where patients experience a dual pattern of congestion and irritation, and provides support that helps ease the overall symptom burden.

The medication is commonly used to help manage symptoms due to the common cold and allergic rhinitis. The product is relevant for easing symptoms that cluster into patterns requiring supportive management, specifically focusing on congestion and irritation.

The medicine is relevant for easing symptoms that interfere with daily functioning, including nasal stuffiness, frequent sneezing, a runny nose, and itching of the eyes or throat. “It is commonly used when symptoms cluster into patterns requiring supportive management.”

It is applied in scenarios where additional management of discomfort is required during episodes of acute viral illness or seasonal allergic flare-ups. By managing these symptoms, Pisu contributes to improved comfort and may assist with maintaining functional stability during periods of heightened symptoms.

Quick Fact: Symptom Support for Nasal Congestion and Allergic Irritation



Regulatory References

  1. NIH DailyMed Consumer Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Pisu?

The population eligibility for Pisu (Pseudoephedrine and Triprolidine) is strictly defined by regulatory labeling, outlining specific contraindications and restrictions.

Absolute Contraindications (Must Not Use)

Classification Ineligible Populations
Age Restriction Children under 12 years (in specific formulations), newborn, or premature infants.
Drug Interaction Patients currently taking or who have taken Monoamine Oxidase Inhibitors (MAOIs) within the preceding 14 days.
Cardiovascular Risk Individuals with severe hypertension, severe coronary artery disease, or phaeochromocytoma.
Organ Function Patients with severe renal impairment or renal failure.

Conditional or Restricted Use

Use of Pisu requires caution or restriction in several populations based on regulatory documents:

  • Organ/Metabolic Function: Patients with severe hepatic impairment or uncontrolled diabetes mellitus.
  • Comorbidities: Individuals with closed angle glaucoma or prostatic hypertrophy.
  • Reproductive Status: Use during pregnancy is restricted (Category C), and the medicine is not recommended for breastfeeding mothers.

Adults and adolescents 12 years and over are generally eligible for use under standard labeled conditions, while use in younger children is subject to strict age limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Pisu is defined by interactions that necessitate strict prohibitions, time separation, and caution regarding additive effects. All documented interaction information is based on governmental regulatory labeling.


Formal Contraindications and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. Due to the risk of a severe hypertensive crisis, the medicine must not be taken concurrently with MAOIs or within 14 days of discontinuing MAOI therapy. The label also prohibits co-administration with other sympathomimetic agents, including decongestants and appetite suppressants, due to the documented risk of severe additive cardiovascular and central nervous system effects. Furthermore, the medicine is contraindicated in patients with severe coronary artery disease or uncontrolled severe hypertension.


Pharmacodynamic Interaction Patterns

The antihistamine component (Triprolidine) interacts with Central Nervous System (CNS) depressants, including alcohol and sedatives, resulting in enhanced sedation and increased impairment of CNS performance. This is classified as a significant additive effect. The decongestant component (Pseudoephedrine) may antagonize the therapeutic effect of certain antihypertensive agents, such as beta-blockers, by interfering with their sympathetic activity. Triprolidine’s anticholinergic effects may be potentiated by co-administered anticholinergic drugs. In the elderly population (65 years and older), there is a heightened risk of neurological anticholinergic effects, including confusion, resulting from these interactions.

Mechanism of Action

Activating the PPARgamma Nuclear Receptor

Pisu functions as an agonist, directly binding to and activating the Peroxisome Proliferator-Activated Receptor gamma ( PPARgamma), a specific nuclear receptor present in fat, muscle, and liver tissues. This initial molecular action triggers changes in gene expression, modifying gene transcription sequences that influence metabolic processes.


Modulating Genes for Metabolic Regulation

The activation of PPARgamma leads to the modulation of specific genes that control glucose and lipid metabolism. This change in protein production, including increased glucose transporters, facilitates an increase in the rate of glucose transport across the cell membrane into peripheral tissues.


Enhancing Cellular Responsiveness to Insulin

The collective changes in gene and protein expression result in enhanced peripheral insulin responsiveness and a decreased output of sugar by the liver. This physiological effect means the target cells increase the rate of insulin-mediated glucose uptake and utilization, which results in altered glucose homeostasis and lipid partitioning.

Dosage and Administration Information

How to Use Pisu: Official Administration Guidelines

The administration of Pisu, the combination of Pseudoephedrine and Triprolidine, is defined by established guidelines to ensure appropriate use according to specifications. The medication is an oral formulation, available as a tablet or a liquid/syrup. Proper use is governed by the established single-dose, frequency, and maximum time limitations published in standard labeling.

Administration Scope Official Instruction
Route of Administration Pisu is administered solely via the oral route.
Standard Adult Dose (≥ 12 years) The required single dose is 1 tablet (60 mg/2.5 mg strength) or 10 mL of the liquid/syrup.
Dosing Frequency Administration occurs every 4 to 6 hours as needed for temporary symptomatic relief.
Maximum Limit The total usage must not exceed 4 doses within any 24-hour period.
Intake Condition The medication can be taken with or without food.

Age-Group Specific Rules

Specific dosage adjustments are mandated for pediatric patients. For children aged 6 to under 12 years, the dose is reduced to precisely ½ tablet or 5 mL of the liquid, taken at the standard 4-to-6-hour interval. This combination product is generally not recommended for use in children under 6 years.

Procedural Administration

When utilizing the oral liquid form, accurate measurement is required using a specialized measuring device to ensure dosage precision. The medication is intended for short-term use only; instructions indicate that use should cease and professional medical advice be sought if symptoms do not improve after 7 days. The total administration protocol is defined by these fixed constraints.

Recent Clinical Evidence

Research evidence / Overview of studies for Pisu


Evidence for Use in Allergic Rhinitis Symptoms

Research exploring the use of Pisu (Pseudoephedrine and Triprolidine combination) for allergic rhinitis relies primarily on short-term randomized controlled trials (RCTs). These studies were generally applied in research contexts involving fluctuating or unstable symptoms, with researchers examining how symptoms change over defined time intervals. The outcomes that were monitored in these trials included patient-reported outcomes describing perceived discomfort related to both nasal symptoms, such as congestion and sneezing, and non-nasal symptoms, including itching of the eyes or throat. This approach helps studies contribute to the broader evidence landscape by providing insight into short-term changes.

In reviewing these studies, findings describe patterns observed in the symptoms of participants with allergic rhinitis. However, when researchers monitored objective physiological measures, such as changes in the nasal airways, findings were mixed regarding the differentiation of components. Some studies reported difficulty in differentiating the observed effects of the combination from the effects of the decongestant component administered alone when using these more technical measurements.

Evidence for Use in Common Cold Symptoms

The research base for Pisu in managing the symptoms of the common cold was evaluated in systematic reviews and meta-analyses. The primary outcomes studied were related to physical discomfort and outcomes capturing phases of heightened symptom activity, typically through the use of Overall Effectiveness Scores reported by the study participants. Data from these research settings show patterns related to short-term changes in the overall burden of symptoms.


Long-Term Research and Follow-up Duration

Research for Pisu, and similar products designed for acute conditions, has largely focused on short-term relief rather than long-term outcomes. The follow-up durations in the main clinical trials were limited, reflecting the typical, temporary nature of common cold and acute allergy flare-ups. The evidence suggests that long-term effects are not fully established, as few studies have explored the durability of symptom pattern changes over several months or longer. Therefore, the available evidence is relevant in trials assessing short-term or episodic symptom patterns.

Evidence in Specific Age Groups and Populations

The majority of studies examining Pisu was observed in adults and older children (typically those age 12 and above). The results apply only to the populations studied, meaning that the evidence is more comprehensive for these age groups who experience conditions where symptoms may vary in intensity. Conversely, data for certain groups remain limited. Specifically, effectiveness data for this class of combination product are considered inadequate for children younger than 6 years old by major regulatory bodies. This research gap means that current evidence provides limited context for studying symptoms in very young children.

Key Studies & References

  1. DailyMed - Pseudoephedrine and Triprolidine Product Listing
  2. DailyMed Consumer Drug Label - Common Uses (Cold and Allergic Rhinitis)
  3. Systematic Review of Oral Decongestant-Antihistamine Combinations for Allergic Rhinitis

Frequently Asked Questions (FAQ)

Common questions about Pisu (FAQ)

Q: What is the main reason Pisu is prescribed?

Official regulatory labels indicate that Pisu is used to temporarily relieve specific symptoms associated with the common cold, such as nasal congestion and runny nose. The product is also indicated for the relief of upper respiratory allergy symptoms, including sneezing and itching of the nose, throat, or eyes.


Q: Is Pisu the same kind of drug as similar ones I've heard about?

Pisu is known as a combination product, meaning it contains two different active components. These components are classified as an antihistamine (Triprolidine) and a decongestant (Pseudoephedrine). Other medicines may contain components that belong to these same drug classes.


Q: How quickly do people typically notice an effect after starting Pisu?

According to official product information, symptom relief is typically noticed relatively quickly after taking a dose. Effects are generally observed within 30 minutes to one hour of administration.


Q: Is it okay to take Pisu every day?

Pisu is intended only for short-term use for temporary symptom relief. The official regulatory label directs that use should not extend beyond the recommended duration. If symptoms do not improve within 7 days of starting the medication, official guidance describes the condition under which a health professional should be consulted.


Q: What happens if I miss a scheduled dose of Pisu?

Official product information describes the general procedure for a missed dose: taking it when remembered, or skipping it if the next scheduled dose is near. This instruction is provided to prevent the administration of two doses too closely together.


Q: Can Pisu affect my mood or sleep?

Official safety information indicates that Pisu can affect sleep patterns, as insomnia is listed as an uncommon adverse reaction. The product may also be associated with nervousness, anxiety, or restlessness. These effects are classified as uncommon.


Q: Can Pisu interact with over-the-counter pain relievers?

The decongestant component of Pisu can safely be combined with many common over-the-counter pain relievers. However, official regulatory guidance describes the practice of checking with a health professional regarding all combined medications.


Q: Do vitamins or supplements change how Pisu works?

Regulatory guidance specifies that the use of all products—including prescription drugs, over-the-counter products, natural products, vitamins, and any herbal supplements—should be reviewed by a health professional.


Q: Is Pisu safe for older adults (seniors)?

Official safety information notes that older adults may be more sensitive to certain effects of Pisu. This population has been observed to have an increased risk of central nervous system effects, such as confusion, and may experience a heightened risk of difficulty passing urine.


Q: What are the safety classifications for Pisu during pregnancy?

Human pregnancy data for Pisu as a combination product is considered limited or unavailable by regulatory bodies. Official guidance specifies the condition under which a health professional should be consulted before using Pisu.


Q: Can women who are breastfeeding use Pisu?

Components of Pisu are known to be present in human milk. Regulatory guidance recommends consultation with a health professional before use for individuals who are breastfeeding, as caution is specified.


Q: Is Pisu known to be addictive or habit-forming?

Pisu is not classified as a controlled substance under the Federal Controlled Substances Act. Official instructions state that the medication is intended only for short-term, temporary use to relieve symptoms.


Q: What does it mean if Pisu is a 'Schedule X' drug?

The Pseudoephedrine component is classified as a List I Chemical by the U.S. Drug Enforcement Administration (DEA). This status requires specific sales restrictions and monitoring, but the combination drug itself is generally not a scheduled controlled substance.


Q: When should someone stop taking Pisu and call a doctor?

Regulatory labels describe the specific conditions that warrant stopping use and consulting a health professional. These conditions include if symptoms do not improve within 7 days, the occurrence of new symptoms, or the onset of nervousness, dizziness, or sleeplessness.


Q: If I feel better, can I just stop taking Pisu?

Pisu is intended for short-term, temporary use to relieve symptoms as they occur. The medication is not typically taken on a long-term continuous basis, and its use is dictated by the presence of acute symptoms.


Q: What happens if I take Pisu for a long period of time?

Pisu is intended for short-term use only. Regulatory guidance specifies that the recommended duration of use should not be exceeded. Furthermore, long-term effects for this combination product are not fully established.


Q: Are there any specific foods or drinks to avoid while on Pisu?

Regulatory guidance recommends limiting or avoiding intake of caffeine-containing foods and beverages. This is because excessive caffeine, when combined with the medication's decongestant component, may increase the risk of side effects such as nervousness, difficulty sleeping, or a rapid heartbeat.


Q: Is Pisu available as a generic version?

Yes, combination products containing Pseudoephedrine and Triprolidine are available in generic formulations.


Q: What is the risk of an allergic reaction to Pisu?

Official safety information lists severe allergic reactions, including severe skin reactions, as a rare but serious adverse reaction. Signs of an allergic reaction may include rash, hives, swelling of the face, or trouble breathing.


Q: What should I do if I think I'm having a bad reaction to Pisu?

Regulatory guidance specifies the immediate actions to be taken, such as seeking medical help or contacting a certified Poison Control Center for assistance, if a severe or serious adverse reaction occurs.


Q: Does Pisu cause stomach upset?

Stomach upset is a possible adverse effect associated with Pisu. The regulatory patient information notes that taking the medication with food may provide relief from this effect.


Q: Why is Pisu only available by prescription?

The regulatory status of products containing the Pseudoephedrine component of Pisu means they are often regulated and kept behind the pharmacy counter or available over-the-counter. They are generally not solely available by prescription.


Q: What official sources provide patient information about Pisu?

Official patient information about Pisu and its components is available from various government sources. These include drug labels and summaries published by the FDA/DailyMed, the NIH/MedlinePlus, and the EMA/SmPC.


Q: Does Pisu have any known interactions with herbal remedies?

Regulatory guidance specifies that the use of all products, including herbal remedies, should be reviewed by a health professional prior to taking Pisu. This is to ensure all potential interactions are assessed.


Q: Is it normal to feel no change when first starting Pisu?

Symptom relief is generally expected to begin within 30 minutes to one hour after taking a dose. If no change is felt, the official label directs the individual to adhere to the maximum dose limit and monitor symptoms.


Q: What if I have kidney or liver issues? Can I take Pisu?

Regulatory guidance specifies that individuals with kidney or liver disease should seek consultation with a health professional. This step is recommended to confirm whether the medication is appropriate for use prior to starting treatment.


Q: Why do some people report feeling worse when they start Pisu?

Official safety information notes that certain common side effects, such as sedation, may be more pronounced and common during the initial days of treatment. This period of heightened effect may contribute to a temporary feeling of increased discomfort.


Q: Does Pisu interact with caffeine?

The stimulant effects of the Pseudoephedrine component may be additive when combined with caffeine. This combination may increase the risk of side effects such as nervousness, rapid heartbeat, or trouble sleeping.

How should Pisu be stored and disposed of?

Storage Requirements

All forms of Pisu (Pseudoephedrine and Triprolidine) must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F), according to official regulatory labeling. The medicine must be kept in its original container to protect it from moisture and light. Liquid forms should not be refrigerated or frozen, as this may compromise product stability.

Disposal Instructions

Unused or expired Pisu should be discarded using a drug take-back program when available. If a take-back program is not accessible, the product may be disposed of in the household trash by mixing it with an unappealing substance (like coffee grounds) in a sealed bag. The label states that the medicine must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pisu found in:

A-Z Index: